Objective 　The purpose of this study, which focuses on the number of the Cochrane Systematic Review’s (CSR) full texts, protocols and registered titles from Chinese authors, is to show the development of evidence-based medicine (EBM) and promote EBM’s further development in China.
Methods 　On the basis of The Cochrane Library (Issue 1, 2009) and the Cochrane Collaboration (March 2009) periodicals, we performed statistical analysis of different countries that released CSR’s full texts, protocols and registered titles, as well as the time, authors and distribution of the CSR’s full texts, protocols and registered titles in China.
Results 　The publishing rates of the CSR’s full texts, protocols and registered titles in China ranked the seventh, fifth and second, respectively. Although the number of CSR’s full texts and protocols showed an increased annual trend in China, the development of area distribution was unbalanced. Moreover, China’s published articles contained 47 Cochrane collaboration groups, without effective practice and health care groups, consumers and communication groups, and methodology and multiple stenosis groups.
Conclusions 　The current Chinese EBM situation has a great potential in writing CSR. However, there are still many problems that need to be resolved.

Citation： JIA Wenqin,YANG Kehu,TIAN Jinhui,ZHANG Pen,LI Lun,MA bin,LIU Yali. Development of China’s Evidence-Based Medicine through the Cochrane Systematic Reviews. Chinese Journal of Evidence-Based Medicine, 2009, 09(6): 635-639. doi: 10.7507/1672-2531.20090115 Copy